Early detection of nasopharyngeal carcinoma by plasma Epstein‐Barr virus DNA analysis in a surveillance program
Authors:
- K. C. Allen ChanKCK. C. Allen Chan
- Emily C. W. HungEHEmily C. W. Hung
- John K. S. WooJWJohn K. S. Woo
- Paul K. S. ChanPCPaul K. S. Chan
- Franco P. T. LaiFLFranco P. T. Lai
- Anita S. M. ChengACAnita S. M. Cheng
- Sze Wan YeungSYSze Wan Yeung
- Yin Wah ChanYCYin Wah Chan
- Teresa K. C. TsuiTTTeresa K. C. Tsui
- Jeffrey S. S. KwokJKJeffrey S. S. Kwok
- Ann D. KingAKAnn D. King
Open Access
- 21 February 2013
- Vol. 119 (10) , 1838-1844
Abstract
BACKGROUND: Nasopharyngeal carcinoma (NPC) is prevalent in Southeast Asia. Over the last decade, plasma Epstein‐Barr virus (EBV) DNA has been developed as a tumor marker for NPC. In this study, the authors investigated whether plasma EBV DNA analysis is useful for NPC surveillance.METHODS: In total, 1318 volunteers ages 40 to 60 years were prospectively recruited. Plasma EBV DNA and serology for viral capsid antigen immunoglobulin A (IgA) were measured. Participants who had detectable plasma EBV DNA or positive IgA serology underwent nasal endoscopic examination and a follow‐up plasma EBV DNA analysis in approximately 2 weeks. All participants were followed for 2 years to record the development of NPC.RESULTS: Three individuals with NPC were identified at enrolment. All of them were positive for EBV DNA and remained positive in follow‐up analysis. Only 1 of those patients was positive for EBV serology. In 1 patient who had NPC with a small tumor confined to the mucosa, the tumor was not detectable on endoscopic examination. Because of a 2‐fold increase in plasma EBV DNA on the follow‐up analysis, that patient underwent magnetic resonance imaging, which revealed the tumor. Among the participants who did not have NPC but had initially positive plasma EBV DNA results, approximately 66% had negative EBV DNA results after a median of 2 weeks.CONCLUSIONS: Plasma EBV DNA analysis proved useful for detecting early NPC in individuals without a clinical suspicion of NPC. Repeating the test in those who had initially positive results differentiated those with NPC from those who had false‐positive results. Cancer 2013. © 2013 American Cancer Society.Keywords
This publication has 19 references indexed in Scilit:
- Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel SequencingClinical Chemistry, 2013
- Mathematical Model Identifies Blood Biomarker–Based Early Cancer Detection Strategies and LimitationsScience Translational Medicine, 2011
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Development of Personalized Tumor Biomarkers Using Massively Parallel SequencingScience Translational Medicine, 2010
- Aberrant Methylation ofAPC, MGMT, RASSF2A, andWif-1Genes in Plasma as a Biomarker for Early Detection of Colorectal CancerClinical Cancer Research, 2009
- Excellent Local Control With Stereotactic Radiotherapy Boost After External Beam Radiotherapy in Patients With Nasopharyngeal CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal CarcinomaJournal of Clinical Oncology, 2006
- Nasopharyngeal carcinomaThe Lancet, 2005
- Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experienceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein–Barr Virus DNA and Anti-Epstein–Barr Viral Capsid Antigen IgA AntibodyClinical Chemistry, 2004